PMID- 35312853
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220409
IS  - 2730-6011 (Electronic)
IS  - 2730-6011 (Linking)
VI  - 13
IP  - 1
DP  - 2022 Mar 21
TI  - Mapping human papillomavirus, Epstein-Barr virus, cytomegalovirus, adenovirus, 
      and p16 in laryngeal cancer.
PG  - 18
LID - 10.1007/s12672-022-00475-4 [doi]
LID - 18
AB  - PURPOSE: Apart from tobacco and alcohol, viral infections are proposed as risk 
      factors for laryngeal cancer. The occurrence of oncogenic viruses including human 
      papilloma virus (HPV) and Epstein-Barr virus (EBV), in laryngeal squamous cell 
      carcinoma (LSCC) varies in the world. Carcinogenesis is a multi-step process, and 
      the role of viruses in LSCC progression has not been clarified. We aimed to 
      analyze the presence and co-expression of HPV, EBV, human cytomegalovirus (HCMV) 
      and human adenovirus (HAdV) in LSCC. We also investigated if p16 can act as 
      surrogate marker for HPV in LSCC. METHODS: Combined PCR/microarrays 
      (PapilloCheck(R)) were used for detection and genotyping of HPV DNA, real-time PCR 
      for EBV, HCMV and HAdV DNA detection, and EBER in situ hybridization (EBER-ISH) 
      for EBV detection in tissue from 78 LSCC patients. Additionally, we analyzed p16 
      expression with immunohistochemistry. RESULTS: Thirty-three percent (26/78) of 
      LSCC tumor samples were EBV positive, 9% (7/78) HCMV positive and 4% (3/78) HAdV 
      positive. Due to DNA fragmentation, 45 samples could not be analyzed with 
      PapilloCheck(R); 9% of the remaining (3/33) were high-risk HPV16 positive and also 
      over-expressed p16. A total of 14% (11/78) of the samples over-expressed p16. 
      CONCLUSION: These findings present a mapping of HPV, EBV, HCMV and HAdV, 
      including the HPV surrogate marker p16, in LSCC in this cohort. Except for EBV, 
      which was detected in a third of the samples, data show viral infection to be 
      uncommon, and that p16 does not appear to be a specific surrogate marker for 
      high-risk HPV infection in LSCC.
CI  - (c) 2022. The Author(s).
FAU - Schindele, Alexandra
AU  - Schindele A
AUID- ORCID: 0000-0003-0007-8716
AD  - Department of Clinical Sciences, Otorhinolaryngology, ONH-Kliniken Ostersunds 
      Sjukhus, Umea University, 831 83, Ostersund, Sweden. alexandra.schindele@umu.se.
FAU - Holm, Anna
AU  - Holm A
AUID- ORCID: 0000-0003-3522-1842
AD  - Department of Clinical Sciences, Otorhinolaryngology, ONH-Kliniken Ostersunds 
      Sjukhus, Umea University, 831 83, Ostersund, Sweden.
FAU - Nylander, Karin
AU  - Nylander K
AUID- ORCID: 0000-0002-4831-4100
AD  - Department of Medical Biosciences, Pathology, Umea University, Umea, Sweden.
FAU - Allard, Annika
AU  - Allard A
AUID- ORCID: 0000-0001-6949-1213
AD  - Department of Clinical Microbiology, Clinical Virology, Umea University, Umea, 
      Sweden.
FAU - Olofsson, Katarina
AU  - Olofsson K
AUID- ORCID: 0000-0002-0649-3825
AD  - Department of Clinical Sciences, Otorhinolaryngology, Umea University, Umea, 
      Sweden.
LA  - eng
GR  - JLL-939740/FoU-enheten, Region Jamtland Harjedalen/
GR  - LP 16-2020/Cancer Research Foundation Northern Sweden/
GR  - LP 16-2020/Cancer Research Foundation Northern Sweden/
GR  - LP 16-2020/Cancer Research Foundation Northern Sweden/
GR  - RV938896/Region Vasterbotten/
GR  - RV938896/Region Vasterbotten/
GR  - RV938896/Region Vasterbotten/
PT  - Journal Article
DEP - 20220321
PL  - United States
TA  - Discov Oncol
JT  - Discover oncology
JID - 101775142
PMC - PMC8938541
COIS- The authors report no conflicts of interest.
EDAT- 2022/03/22 06:00
MHDA- 2022/03/22 06:01
PMCR- 2022/03/21
CRDT- 2022/03/21 17:18
PHST- 2022/01/03 00:00 [received]
PHST- 2022/03/02 00:00 [accepted]
PHST- 2022/03/21 17:18 [entrez]
PHST- 2022/03/22 06:00 [pubmed]
PHST- 2022/03/22 06:01 [medline]
PHST- 2022/03/21 00:00 [pmc-release]
AID - 10.1007/s12672-022-00475-4 [pii]
AID - 475 [pii]
AID - 10.1007/s12672-022-00475-4 [doi]
PST - epublish
SO  - Discov Oncol. 2022 Mar 21;13(1):18. doi: 10.1007/s12672-022-00475-4.